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Letters to the EditorAnemia as a potential contributor to bleeding in patients with
liver disease – Neglected but not forgottenReply to Dr. Tachil:
We appreciate the interest of Dr. Thachil in our recently published
meeting report on coagulation disorders in patients with liver dis-
ease [1]. Dr. Thachil states that the anemia of liver disease may be
important in the bleeding manifestations in these patients, with
whichwe fully agree. The role of anemia was simply not discussed
during the 3rd International Symposium on Coagulopathy and
Liver disease, highlights of which were summarised in the meet-
ing report. Whereas the omission of the role of anemia in the con-
ference programme is the responsibility of us as conference
organisers, we havemade a case for the role of anemia in the coag-
ulopathy of liver disease in previous publications [2,3]. We fully
agree that red cells are important in the hemostatic process, in
particular due to the effects of red cells on platelet attachment
to the damaged vasculature in ﬂowing blood. In fact, experimental
evidence from us and others has indicated that anemia is a key
factor in platelet hypofunction studied in ex vivo experimental
models [2,4]. Furthermore, as also mentioned by Dr. Thachil, cor-
rection of anemia in patients with renal disease by red cell trans-
fusion or administration of erythropoietin appears to reduce
uremic bleeding. Nevertheless, we do believe clinical evidence
supports the concept of ‘rebalanced hemostasis’ in liver disease
[5]. More and more centers report that a large proportion of
patients can undergo a liver transplantation without any require-
ments for blood product transfusion despite persistent periopera-
tive anemia (reviewed in [5]).
The rebalanced hemostasis theory explains these observa-
tions by the presence of compensatory factors for thrombocyto-
penia (high levels of von Willebrand factor) and decreased
levels of procoagulant and antiﬁbrinolytic proteins (i.e.,
decreased levels of anticoagulant and proﬁbrinolytic proteins).
No compensatory factor for anemia appears present, although
as mentioned in our meeting report, platelet function in vivo
could be promoted by a reduced glycocalix on the vascular
endothelium. To our knowledge experimental data on a possible
role of reduced endothelial glycocalix in promoting platelet
function in the anemic and thrombocytopenic patient with cir-
rhosis are not available, but experiments testing this hypothesis
would be of interest.594 Journal of Hepatology 2As discussed in the meeting report, bleeding episodes do
occur in patients with liver disease, and also during liver trans-
plantation severe bleeding can on occasion be encountered.
Reversal of anemia may thus be of beneﬁt for the patient with
liver disease by reducing bleeding risk, and we agree with Dr.
Thachil that clinical studies on this issue are worthwhile. We
have recently proposed outlines for clinical studies on the pre-
vention of bleeding or thrombosis in patients with liver disease
[5] and agree that randomised controlled studies on reduction
of bleeding during invasive procedures by red cell transfusion
or administration of erythropoietin and intravenous iron would
also be of interest. These studies, however, should carefully
assess potential risks associated with these therapeutic strate-
gies. We and others have recently demonstrated that transfusion
of red cell concentrates during liver transplantation is associated
with increased morbidity and mortality [6]. Accumulating clinical
and laboratory evidence suggests that a restrictive transfusion
policy, which includes acceptance of a low hematocrit, during
liver transplantation is safe and effective (reviewed in [5]). Trans-
fusion of red cell concentrates to patients with liver failure may
result in aggravation of portal hypertension, which may even par-
adoxically induce or facilitate bleeding. These effects demon-
strated both experimentally and clinically (reviewed in [7]) led
to recommendations that red cell transfusions be limited in var-
iceal bleeding with a target hemoglobin between 7 and 8 g/dl in
the Baveno V criteria [8]. One could argue that a slightly higher
value or use of a hematocrit target of 25% might better balance
between effective platelet rheology and portal pressure as the ini-
tial platelet plug probably plays some role in variceal bleeding
cessation, although pressure effects dominate.
The effects of red cell transfusion on hemostasis in the patient
with liver failure and portal hypertension are thus complex, and
clinical studies should therefore assess both efﬁcacy and safety.
In our opinion, current evidence suggest that a restrictive trans-
fusion policy, which includes restrictive use of red cell concen-
trates should be standard of care until randomised clinical
studies suggest otherwise. Administration of erythropoietin
may be a more attractive therapeutic strategy in patients with
liver disease, as an unwanted volume expansion is avoided.011 vol. 54 j 588–595
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Moreover, erythropoietin has the advantage of also stimulating
thrombopoiesis to some extent [9]. Nevertheless, erythropoietin
has been associated with an increased risk of thrombosis in crit-
ically ill patients, which may be of concern [10].
In summary, we concur with Dr. Thachil that the anemia of
cirrhosis may be linked to bleeding. We welcome clinical studies
on anemia reversal to prevent bleeding in these patients, but
these studies should take potential side effects into account.
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